Toronto, Ontario March 20, 2014 Dalton Pharma Services, a privately owned pharmaceutical services provider to leading pharmaceutical and biotechnology companies, today announces the completion of a $2.5 million expansion of its sterile and aseptic filling capabilities. This project included addition of sterile vial processing and washing, expanded vial depyrogenation capability, automated vial inspection capability, new Water For Injection (WFI) system, and expanded and improved gowning areas for GMP manufacturing operators.
"This is an important step in our strategic plan for increasing sterile filling capabilities at Dalton,” said Peter Pekos, President and CEO. “I am grateful for the hard work of our senior management and our key contractors that enabled completion of this key phase on schedule.”
“Besides increasing our overall capacity,” he added. “This expansion will allow us to provide our clients with more complete and efficient manufacturing services. The focus of future stages of the expansion will be the addition of high value capabilities supporting large and small molecule manufacturing development. The next stage of expansion is scheduled to begin later this year. Our overall goal continues to be the offering of fully integrated sterile manufacturing services from preclinical to commercial production, for both API and finished doses.”
Click here to view the full news release online.